Medicxi

About The Fund

Medicxi is a life sciences-focused venture capital firm with a profound orientation towards healthcare, biotechnology, and the pharmaceutical sector. Established in 2016 and headquartered in London, United Kingdom, Medicxi operates on a philosophy of supporting innovation in the life sciences domain. With additional offices in Geneva, Switzerland, and Saint Helier, United Kingdom, the firm's geographic footprint underpins its strategic investments across different hubs of scientific and entrepreneurial activity within its sector focus. Medicxi specializes in equity investments, catering to various stages of business development, including seed, startup, early stage, expansion, and later stage ventures. The fund manages assets worth $500 million, which is indicative of substantial financial capabilities to drive and support groundbreaking advancements in life sciences. Medicxi’s investment thesis anchors on identifying and nurturing high-potential enterprises that are poised to redefine the realms of biotech, academia, and pharmaceuticals. Their portfolio encapsulates a broad spectrum of industries including Software focusing on Web Marketplace SaaS, BioTech, Business Solutions, Hardware and Manufacturing, Food and Beverage, Logistics and Distribution, Medical Devices and Hospital Services, Life Science, Nanotechnology, Oncology, and Pharmaceutical and Medicine. Medicxi’s commitment to innovation is evident in their backing of ventures such as Ottimo Pharma, which recently raised over $140 million in Series A funding to develop novel bi-functional antibodies. They also hold stakes in Vicebio, which has initiated Phase 1 Clinical Study for an RSV/hMPV Bivalent Vaccine, and Levicept, which announced positive results of a Phase II trial of a new Neurotrophin-3 Inhibitor for osteoarthritis treatment. Medicxi’s approach combines financial investment with strategic guidance, leveraging the firm’s expertise and networks to maximize the potential of their investee companies.